The chimeric, monoclonal antibody (mAb) wc6D5 was developed by Bristol Myers Squibb for targeting woodchuck PD-L1, which resembles the human anti-PD-L1 antibody, BMS 936559, used in the anti-cancer treatment of patients [87]. This evidence concerns the gene CD274 and cancer.